3 Red Flags for Biogen's Future
If you're a former Biogen (NASDAQ: BIIB) investor like me, you might feel compelled to warn other people away from the stock. Since the U.S. Food and Drug Administration (FDA) approved its controversial Alzheimer's drug Aduhelm in mid-2021, very little has gone right for the pharma company. Its shares have fallen by more than 31% in the last three years, and in my view, there's even more difficulty to come.
Unless you're an especially daring investor, you should probably consider stepping away from this stock. Here are three critical issues that explain why.
Image source: Getty Images.
Source Fool.com
